Pipeline
| Drug | Indications | Preclinical | IND | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| Prexigebersen BP1001 |
AML | |||||
| BP1001-A | Solid Tumors e.g. ovary, endometrium | |||||
| BP1002 Liposomal Bcl-2 |
CLL, Lymphoma | |||||
| BP1002 Liposomal Bcl-2 |
Refractory/relapsed AML (Including those who have relapsed after Bcl-2 inhibitor treatment) | |||||
| BP1003 Liposomal STAT3 |
Solid Tumors (e.g. pancreas, lung) | |||||
| Drug | Indication | Stage | Prexigebersen BP1001 |
AML | Phase 2 |
|---|---|---|
| BP1001-A | Solid Tumors e.g. ovary, endometrium | Phase 1 |
| BP1002 Liposomal Bcl-2 |
CLL, Lymphoma | Phase 1 |
| BP1002 Liposomal Bcl-2 |
Refractory/relapsed AML (Including those who have relapsed after Bcl-2 inhibitor treatment) | Phase 1 |
| BP1003 Liposomal STAT3 |
Solid Tumors (e.g. pancreas, lung) | IND |
